Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI) has been given an average rating of “Moderate Buy” by the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $38.91.

A number of equities analysts have issued reports on DNLI shares. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. HC Wainwright reduced their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday. Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $31.00 target price for the company. Finally, Jefferies Financial Group lifted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now directly owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. The trade was a 14.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 1,020 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 104,518 shares of company stock worth $2,576,982. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CWM LLC increased its position in shares of Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC acquired a new stake in shares of Denali Therapeutics in the third quarter worth $73,000. Assetmark Inc. raised its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after acquiring an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Denali Therapeutics during the 2nd quarter valued at approximately $194,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 0.3 %

Shares of DNLI stock opened at $21.25 on Friday. The stock has a 50 day moving average of $24.23 and a 200-day moving average of $24.86. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33. The firm has a market cap of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the company earned ($0.72) EPS. As a group, equities analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.